Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This specific multi-ingredient Chinese herbal formula (CHF) was developed by researchers at Chang Gung Memorial Hospital for the treatment of atopic dermatitis (AD). The formula is a combination of two classical traditional Chinese medicine (TCM) prescriptions, Xiao-Feng-San and Zhen-Ren-Huo-Ming-Yin, supplemented with the individual herbs *Dictamnus dasycarpus* and *Houttuynia cordata*. Administered orally in capsule form, the formula is designed to modulate the immune system by regulating the levels of Th1, Th2, Th17, and Th22-related cytokines and addressing microbiome dysfunction associated with the disease. It is currently being evaluated in a Phase 3 clinical trial to assess its clinical efficacy, safety, and impact on plasma metabolites in patients with atopic dermatitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mixed Chinese Herbal Formula.